Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.
EBS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
Below please find a table outlining a discounted cash flow forecast for EBS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Emergent BioSolutions Inc ranked in the 56th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 51%. In terms of the factors that were most noteworthy in this DCF analysis for EBS, they are:
Interest coverage, a measure of earnings relative to interest payments, is 8.13 -- which is good for besting 65.77% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
Emergent BioSolutions Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.74% of tickers in our DCF set.
Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 19 -- greater than 76.27% of US stocks with positive free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
HRC, MCK, DXCM, PRAH, and ACIU can be thought of as valuation peers to EBS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
ANN ARBOR, Mich.--(BUSINESS WIRE)-- #bioindustry--MichBio welcomes Uma Sharma, PhD Chief Scientific Officer at MMS Holdings and Ron Perry Vice President and General Manager at Emergent BioSolutions to the Board of Directors. Uma Sharma, PhD was appointed in mid-August to complete a term expiring in December 2021. As the CSO of MMS Holdings, she is a hands-on leader focused on guiding sponsors on clinical strategy and colleagues through an inclusive leadership model. Dr. Sharma has a personal philosophy of pay
The FDA has approved Emergent BioSolutions' (EBS) shelf life extension of NARCAN (naloxone HCl) Nasal Spray from 24 months to 36 months.Narcan Nasal Spray was the first intranasal form of naloxone approved for the emergency treatment of known or suspected opioid overdose....
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDA...